Q3 EPS Forecast for Aprea Therapeutics Raised by Analyst

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities researchers at HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for shares of Aprea Therapeutics in a report issued on Wednesday, August 12th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.09) per share for the quarter, up from their previous forecast of ($0.23). The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Aprea Therapeutics’ Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.39) EPS.

Several other analysts have also weighed in on the stock. Oppenheimer began coverage on shares of Aprea Therapeutics in a research report on Thursday, May 7th. They set an “outperform” rating and a $5.00 target price on the stock. Wedbush dropped their price objective on Aprea Therapeutics to $3.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $3.07.

Aprea Therapeutics Trading Down 1.8%

Shares of NASDAQ:APRE opened at $0.67 on Friday. The firm has a market capitalization of $8.31 million, a PE ratio of -0.62 and a beta of 1.52. Aprea Therapeutics has a 1-year low of $0.55 and a 1-year high of $1.79. The business’s 50 day moving average is $0.71 and its 200-day moving average is $0.77.

Aprea Therapeutics (NASDAQ:APRE) last released its earnings results on Wednesday, August 12th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.11. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 56.85%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in APRE. AIGH Capital Management LLC raised its stake in shares of Aprea Therapeutics by 174.1% during the first quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after buying an additional 645,000 shares during the last quarter. DRW Securities LLC bought a new position in shares of Aprea Therapeutics in the 4th quarter worth $103,000. Finally, Jane Street Group LLC bought a new stake in Aprea Therapeutics in the fourth quarter valued at about $40,000. 34.19% of the stock is currently owned by institutional investors and hedge funds.

About Aprea Therapeutics

Aprea Therapeutics is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.